Search - tctmd.com

Displaying 321 - 340 of 785

Sort: Relevancy | Date

Presentation ESC 2017

BIOFLOW V Comparison of Ultrathin Sirolimus-Eluting Bioresorbable Polymer with Thin Everolimus-Eluting Durable Polymer Stents

Presenter: David E Kandzari

September 13, 2017

News Conference News ESC 2017

BIOFLOW V: ‘Ultrathin-Strut’ Stent Beats Out Xience at 12 Months

Shelley Wood

August 30, 2017

News Industry News

STENTYS Completes Enrollment in the Study Assessing the Safety and Efficacy of Xposition S in Left Main Artery Lesions

July 28, 2017

News Features EuroPCR 2017

Seven Next-Generation Bioresorbable Scaffolds Show Promise but Face Major Hurdles

Yael L. Maxwell

June 01, 2017

News Industry News

STENTYS: Follow-Up of the APPOSITION IV and OPEN II Clinical Trials at Respectively 3 and 4 Years Confirms the Initial Positive Study Outcomes

May 25, 2017

News Conference News EuroPCR 2017

BIO-RESORT: Impaired Glucose Metabolism Linked With Worse Clinical Outcomes After PCI

Michael O'Riordan

May 18, 2017

News Industry News

Micell Technologies Announces MiStent Achieved Primary Endpoint in All-Comers Randomized Clinical Trial Versus Xience

May 16, 2017

News Conference News EuroPCR 2017

DESSOLVE III: MiStent Holds Up Well Against Xience at 12 Months, Hints at Potential Longer-Term Benefit

Michael O'Riordan

May 16, 2017

News Conference News EuroPCR 2017

EuroPCR 2017: New Stents, New Questions for PCI Today and Tomorrow as Angioplasty Turns 40

Shelley Wood

May 12, 2017

News Conference News ACC 2017

ABSORB III: Two-Year Results Show a Higher MACE Rate Compared With Xience

Michael O'Riordan

March 18, 2017

News Conference News ISET 2017

Bioresorbable Scaffolds for PAD: Does the Strategy Have Legs?

Caitlin E. Cox

February 17, 2017

Presentation

10-Year Clinical Outcome After Randomization to Sirolimus- or Paclitaxel-Eluting Coronary stents

February 13, 2017

Presentation JIM 2017

Preliminary Clinical Results with the New Sirolimus Drug Coated Balloon

Presenter: Bernardo Cortese

February 10, 2017

News Daily News

10-Year Follow-up of Early DES Shows Steady Risk of Late Events

L.A. McKeown

February 08, 2017

News Daily News

After EXCEL and NOBLE, New Meta-analysis Revisits PCI vs Surgery for Unprotected Left Main CAD

Michael O'Riordan

December 14, 2016

News Industry News

Micell Technologies Announces First Patient Enrolled In Landmark Registration Trial of MiStent In Japan

November 29, 2016

News Conference News TCT 2016

Novel SES Fails to Match Xience EES for Chronic Total Occlusions

Yael L. Maxwell

November 08, 2016

News Industry News

Positive Five-Year Clinical Data from Micell Technologies’ MiStent Presented at TCT 2016

November 03, 2016

News Industry News TCT 2016

Hybrid Sirolimus-Eluting Stents with Biodegradable Polymer Did Not Improve Angiographic Outcomes Compared to Everolimus-Eluting Stents with Durable Polymer in Treatment of Chronic Total Occlusions

November 02, 2016

Presentation TCT 2016

PRISON IV: A Prospective, Randomized Trial of a Bioresorbable Polymer-Based Sirolimus-Eluting Stent and a Durable Polymer-Based Everolimus-Eluting Stent in Patients With Coronary Artery Chronic Total Occlusions

Presenter: Gary S. Mintz, Robert-Jan van Geuns, Koen Teeuwen

November 02, 2016

Advertisement

BIOFLOW V Comparison of Ultrathin Sirolimus-Eluting Bioresorbable Polymer with Thin Everolimus-Eluting Durable Polymer Stents

BIOFLOW V: ‘Ultrathin-Strut’ Stent Beats Out Xience at 12 Months

STENTYS Completes Enrollment in the Study Assessing the Safety and Efficacy of Xposition S in Left Main Artery Lesions

Seven Next-Generation Bioresorbable Scaffolds Show Promise but Face Major Hurdles

STENTYS: Follow-Up of the APPOSITION IV and OPEN II Clinical Trials at Respectively 3 and 4 Years Confirms the Initial Positive Study Outcomes

BIO-RESORT: Impaired Glucose Metabolism Linked With Worse Clinical Outcomes After PCI

Micell Technologies Announces MiStent Achieved Primary Endpoint in All-Comers Randomized Clinical Trial Versus Xience

DESSOLVE III: MiStent Holds Up Well Against Xience at 12 Months, Hints at Potential Longer-Term Benefit

EuroPCR 2017: New Stents, New Questions for PCI Today and Tomorrow as Angioplasty Turns 40

ABSORB III: Two-Year Results Show a Higher MACE Rate Compared With Xience

Bioresorbable Scaffolds for PAD: Does the Strategy Have Legs?

10-Year Clinical Outcome After Randomization to Sirolimus- or Paclitaxel-Eluting Coronary stents

Preliminary Clinical Results with the New Sirolimus Drug Coated Balloon

10-Year Follow-up of Early DES Shows Steady Risk of Late Events

After EXCEL and NOBLE, New Meta-analysis Revisits PCI vs Surgery for Unprotected Left Main CAD

Micell Technologies Announces First Patient Enrolled In Landmark Registration Trial of MiStent In Japan

Novel SES Fails to Match Xience EES for Chronic Total Occlusions

Positive Five-Year Clinical Data from Micell Technologies’ MiStent Presented at TCT 2016

Hybrid Sirolimus-Eluting Stents with Biodegradable Polymer Did Not Improve Angiographic Outcomes Compared to Everolimus-Eluting Stents with Durable Polymer in Treatment of Chronic Total Occlusions

PRISON IV: A Prospective, Randomized Trial of a Bioresorbable Polymer-Based Sirolimus-Eluting Stent and a Durable Polymer-Based Everolimus-Eluting Stent in Patients With Coronary Artery Chronic Total Occlusions

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content